Our findings suggesting that the level of secretion of VEGFA mediates drug response to regorafenib could be the first step of identifying a biomarker for response to regorafenib and it would be interesting to assess particularly VEGF-A, but also FGF-2 and PDGF-BB in tumour samples in the clinical context such as our FaR-RMS platform trial in the relapse setting where two therapeutic regimens -vincristine, irinotecan and temozolomide versus the experimental arm of vincristine, irinotecan and regorafenib are investigated in randomized fashion (2). Here, VEGFA is linked to neoplasm.